|
Venturing
into the unknown
The Indian pharma industry requires entrepreneurs to blossom.
Yet, there are few takers for their proposals. Nandini Patwardhan
ascertains why PE funding out does venture capital in India
Upfront
Ethypharm
announces out-licensing deal
Ethypharm, a French multinational drug delivery company, announced
the finalisation and signing of a new out-licensing and supply
contract for the Colombian market with Euroetika, a leading
Colombian drug company. Its owned subsidiary, Ethypharm LL
India, will supply the products.
Sun
Pharma plans to de-merge R&D
While a lot of pharma companies are chanting the mergers and
acquisitions mantra, Sun Pharma plans to swim against the
trends by going through a de-merger.
GlaxoSmithKline
Pharmaceuticals' Net Profit up 15.1 percent
GlaxoSmithKline Pharmaceuticals posted a profit after tax
and before exceptional items of Rs 306.28 crores in the year
ended December 31, 2005.
Strides
Arcolab's global revenue grows 44 percent
Strides Arcolab has recorded consolidated global revenue for
the year ended Dec 31, 2005 of Rs 5326 million registering
an annualised increase of 44 percent.
Orchid
enters into long term R&D tie-up with Pfizer
The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals
announced the signing of a long-term master R&D agreement
with Pfizer International.
Cipla
is all set to fight bird flu battles
Cipla has received an approval from the drug controller of
India for marketing the generic version of bird flu drug Oseltamivir,
in the domestic market this month.
Aptuit
ramps up investment with acquisition of InfoPro Solutions
Aptuit, a leader in drug development services, announced that
it will acquire InfoPro Solutions, an information technology
services company that delivers application systems to pharmaceutical
and biotechnology customers.
Stock
Watch
Bird
flu makes drug stocks fly
If bird flu scare has spelled doom to poultry farmers, it
has brought about a streak of luck to drugmakers in the race
for influenza drugs.
|
